Skip to main content

Galera Therapeutics, Inc.

corporate_fare Company Profile

Galera Therapeutics, Inc.

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy that is in Phase 2a clinical trial. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Exchange: OTCSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed GRTX - Latest Insights

GRTX
Apr 27, 2026, 4:14 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
GRTX
Apr 22, 2026, 9:23 AM EDT
Filing Type: 425
Importance Score:
7
GRTX
Apr 20, 2026, 4:58 PM EDT
Filing Type: DEF 14A
Importance Score:
9
GRTX
Apr 14, 2026, 2:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
10
GRTX
Apr 14, 2026, 9:18 AM EDT
Filing Type: 8-K
Importance Score:
10
GRTX
Apr 14, 2026, 8:56 AM EDT
Source: Dow Jones Newswires
Importance Score:
10
GRTX
Apr 10, 2026, 4:01 PM EDT
Filing Type: PRE 14A
Importance Score:
9
GRTX
Apr 10, 2026, 12:29 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
GRTX
Apr 09, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
GRTX
Mar 19, 2026, 7:15 AM EDT
Filing Type: 10-K
Importance Score:
9
GRTX
Feb 18, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
8
GRTX
Feb 12, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
9